FDA warned Nova Kratom that its kratom products are unapproved new drugs marketed to treat opioid addiction and withdrawal.
What happened
In June 2023, FDA reviewed www.novakratom.com and found it took orders for kratom products such as Red Vein, White Vein, Green Vein, and Yellow Vein kratom powders. The website claimed the products could treat opioid addiction and withdrawal, pain, anxiety, depression, and other conditions. FDA said the products are unapproved new drugs because these uses are not FDA-approved.
What FDA found
The company marketed kratom products with claims that they treat opioid addiction and withdrawal, so FDA treats them as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are new drugs because they are not generally recognized as safe and effective for those uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)The products lack FDA approval and were introduced into interstate commerce, which the law prohibits.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks the company to write within fifteen working days of receiving the letter with the specific steps it has taken to correct the violations, how it will prevent recurrence, and supporting documents. If it believes the products are not violations, it must include its reasoning and supporting information.
Who should pay attention
- retailers and distributors selling kratom products
- kratom brands that make health or withdrawal claims
- companies reviewing website claims for unapproved drugs
This is a summary. Read the original letter on fda.gov.